Trial Search Results

Selegiline Patch for Treatment of Nicotine Dependence

Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institute on Drug Abuse (NIDA)

Stanford Investigator(s):


  • Drug: Selegiline
  • Other: matching placebo


Phase 2


Inclusion Criteria:

   - Smokes greater than 20 cigarettes per day

Exclusion Criteria:

   - History of Parkinson's disease, high blood pressure, or severe liver or kidney disease

   - Current substance abuse

   - Mental illness

   - Skin conditions that could interfere with patch use

   - Using antidepressant medications (e.g., levodopa/carbidopa, methyldopa, or any MAO

   - Pregnant or breastfeeding

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joel Killen